Medigene participates at upcoming virtual conferences

Martinsried/ Munich – Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that all mentioned conferences will be conducted virtually due to COVID-19.

Cell Therapy Manufacturing & Gene Therapy Congress
Date: 19 – 22 October

TCR Therapies Summit
Date: 26 – 29 October

BIO-Europe Digital
Date: 26 – 29 October

Neoantigen Based Therapies Summit
Date: 3 – 5 November

35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020)
Date: 9 – 14 November

62nd ASH Annual Meeting and Exposition
Date: 5 – 8 December

– end of announcement –


Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Dr Gary Waanders, Dr Anna Niedl
Tel.: +49 89 2000 3333 01

This site is registered on as a development site.